FTDI
MRNA icon

First Trust Direct Indexing’s Moderna MRNA Stock Holding History

First Trust Direct Indexing’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-6,945
Closed -$825K – 998
2024
Q2 		$825K Buy
6,945
+2,021
+41% +$256K 0.05% 361
2024
Q1 		$525K Buy
4,924
+1,188
+32% +$120K 0.04% 462
2023
Q4 		$372K Buy
+3,736
New +$314K 0.03% 518
2023
Q3 		– Sell
-2,527
Closed -$307K – 727
2023
Q2 		$307K Buy
2,527
+153
+6% +$20.4K 0.03% 542
2023
Q1 		$365K Sell
2,374
-407
-15% -$67.1K 0.04% 483
2022
Q4 		$500K Buy
2,781
+753
+37% +$123K 0.07% 383
2022
Q3 		$240K Sell
2,028
-268
-12% -$40.7K 0.04% 525
2022
Q2 		$328K Buy
2,296
+273
+13% +$39K 0.05% 449
2022
Q1 		$348K Buy
2,023
+552
+38% +$92.9K 0.04% 459
2021
Q4 		$374K Sell
1,471
-64
-4% -$18.7K 0.05% 436
2021
Q3 		$591K Buy
+1,535
New +$566K 0.08% 298

Other funds holding MRNA

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
TP
Theleme Partners London, United Kingdom $1.5B AUM 19.72% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

First Trust Direct Indexing's MRNA Position: Q3 2024 in Review

First Trust Direct Indexing sold out of Moderna (MRNA) in Q3 2024, closing a stake of 6,945 shares — an estimated $825K sold.

First Trust Direct Indexing first reported a position in MRNA in Q3 2021 and held it in 11 quarters. The position peaked at $825K in Q2 2024. 788 funds tracked by Wall St. Rank hold MRNA as of Q3 2024.

  • First Trust Direct Indexing reported no remaining Moderna position as of Q3 2024 after selling out during the quarter.
  • First Trust Direct Indexing sold 6,945 Moderna shares in Q3 2024, an estimated $825K.
  • First Trust Direct Indexing first reported a position in Moderna in Q3 2021 and held it in 11 quarters.
  • First Trust Direct Indexing's Moderna position peaked at $825K in Q2 2024.
  • 788 funds tracked by Wall St. Rank held Moderna as of Q3 2024.

Based on First Trust Direct Indexing's 13F filing for Q3 2024, filed 25 Oct 2024.